Global Gastroenteritis Treatment Market – Industry Trends and Forecast to 2029

Gastroenteritis Treatment Market Analysis and Size

The global gastroenteritis treatment market is expected to witness significant growth during the forecast period. World Health Organization (WHO) reports that diarrheal diseases are a major cause of hospitalizations and child deaths worldwide. Viral gastroenteritis is one of the contagious infection that is generally known as stomach flu which is caused due to more than 20 types of viruses. Sudden outbreak of the COVID-19 pandemic imposed stringent lockdown regulations globally, causing interruptions in import and export activities of global arachnoiditis treatment market.

Data Bridge Market Research analyses a growth rate in the global gastroenteritis treatment market in the forecast period 2022-2029. The expected CAGR of global gastroenteritis treatment market is tend to be around 6% in the mentioned forecast period. The market was valued at USD 35 billion in 2021, and it would grow upto USD 55.78 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Gastroenteritis Treatment Market Scope and Segmentation

Market Definition

Gastroenteritis, also known as stomach flu, is defined as the inflammatory disorder of the gastrointestinal tract, including the stomach and small intestine. It is caused by a virus, bacteria, or parasites and can be spread through contaminated food or water. There is no proper complete cure for gastroenteritis hence prevention is the only cure. Symptoms  include vomiting, nausea, and cramps and muscle ache. This disease prevalence is rising and important diagnostic procedures and treatments will boost the growth of the market.

Global Gastroenteritis Treatment Market Dynamics

Drivers

• Increased Gastrointestinal Disorders

As per the records of the Centers for Disease Control and Prevention (CDC), it is projected that around 1-1.3 million people are suffering from Inflammatory Bowel Disease (IBD) in U.S. Incidence of Crohn’s disease and ulcerative colitis is 201 per 100,000 adults and 238 per 100,000 adults, respectively. thus boosting the market growth.

• Higher Rate of Drug Approvals and Launches       

An extensive range of new generation therapeutics targets which includes novel small molecules and cellular therapy are currently under process. These include mongersen, tofacitinib, ustekinumab, and vedolizumab. This influx is expected to be a consequence of rising prevalence of gastrointestinal diseases worldwide. In addition to this, Vedolizumab is developing as a first-line biologic therapy for Crohn’s disease. Currently, the U.S. FDA has approved Humira, Amjevita, Remicade, Renflexis, Cimzia, Inflectra, Tysabri, and Entyvio for the treatment of Crohn’s disease. Thus, all these developments are boosting the growth of the market.

Opportunities

• High-end Efficiency of Biologics

Some studies have specified that biologics show greater long-term efficiency. According to a study which was conducted by University of Chicago, it was witnessed that the usage of biologics has resulted in a complete reduction in the number of surgeries by around 40.0%, emergency room visits by 60.0%, and hospitalizations by 50.0%. All these factors are also contributing in the growth of the market.  

• The Wide Application of Generic Drugs

Branded drug manufacturers and generic producing firms are joining up together for the production of generic drugs after patent expiry, which is projected to lift the growth of generics. In addition to this, major firms are gradually focusing on developing generics due to increase in off-patented drugs in the market. Although, marketing exclusivity given by the FDA to patent holders for several indications is predicted to hamper market growth to a slight extent.

Restraints/Challenges

• Higher Expenditure Associated With Gastroenteritis Treatment

High-end expenditure with regards to the drug manufacturing and development process are hampering the growth of the market. High initial investment that is required in the R&D activities for the development of vaccines, drugs, and kits that are used in the treatment are restraining growth of the gastroenteritis treatment market.

• Unavailability of Appropriate Treatments

To treat conditions which are rare, many a times all treatments are not available, especially in the under-developed countries. The severe patients needs to be treated with the advanced techniques but at times, these are not available in the hospitals and clinics. Thus, it hampers the market growth.

This global gastroenteritis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global gastroenteritis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Gastroenteritis Treatment Market

 During the pandemic, it has been witnessed that gastrointestinal disorders are greatly associated with COVID-19 patients. The severity of COVID-19 is combined with a set of comorbidities such as diabetes, obesity, hypertension, and/or advanced age that seriously aggravates the consequences of the infection. Additionally, gastrointestinal symptoms, such as vomiting, diarrhea, or abdominal pain during the early phases of COVID-19 are also witnessed. Thus, diagnosing gastrointestinal symptoms that lead respiratory problems during COVID-19 became necessary for early detection and treatment. Thus, COVID-19 left a major impact on global gastroenteritis treatment market.

Global Gastroenteritis Treatment Market Scope

The global gastroenteritis treatment market is segmented on the basis of treatment, route of administration,end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Antibiotic Therapy
• Penicillins
• Cephalosporins
• Dehydration Therapy
• Others 

Route of Administration

• Oral
• Parenteral

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Gastroenteritis Treatment Market Regional Analysis/Insights

The global gastroenteritis treatment market is analysed and market size insights and trends are provided by treatment, route of administration,end-user, distribution channel as referenced above.

The major countries covered in the global gastroenteritis treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is considered to have the highest lucrative growth in the forecast period due to the high-income of the countries and advanced healthcare facilities.

Asia-Pacific is dominating the market due to rapidly aging population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Gastroenteritis Treatment Market Share Analysis

The global gastroenteritis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global gastroenteritis treatment market.

Key players operating in the global gastroenteritis treatment market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)

• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Merck & Co., Inc. (U.S.)
• Lilly (U.S.)
• Amgen Inc. (U.S.)
• Hainan Poly Co. Ltd (China)
• WOCKHARDT (India)

SKU-54135